Athersys
Share
Athersys is a clinical-stage biotechnology company developing novel and proprietary best-in-class th
Athersys is a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our focus is on the treatment of medical conditions where there is significant unmet clinical need, and we are particularly focused on developing therapies in the regenerative medicine area. We are developing MultiStem®, a patented, adult-derived “off-the-shelf” stem cell product platform, for multiple disease indications in the areas of neurological, cardiovascular disease, inflammatory and immune disease, as well as other areas.We have currently six clinical stage programs – including a Phase 2 study in ischemic stroke, a Phase 2 clinical study for the treatment of damage from acute myocardial infarction, a exploratory clinical study in Acute Respiratory Distress Syndrome, and several others. We also have a portfolio of preclinical programs that we are advancing toward clinical stage development. Athersys has forged a network of strategic alliances and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research and clinical institutions, in the United States, Japan and Europe to further develop its platform and products.
11/17/2023
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announce
10/16/2023
Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives
Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) fo
10/10/2023
Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios
Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, a
10/06/2023
We're excited for Alliance for Regenerative Medicine's next week! Looking forward to connecting with senior executives and key stakeholders in the cell and gene therapy industry.
Cell & Gene Meeting on the Mesa The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures.
10/03/2023
Athersys Licenses its Animal Health Assets to Ardent Animal Health
Athersys Licenses its Animal Health Assets to Ardent Animal Health Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, a
10/03/2023
We are excited to announce that Jane Wasman, JD, has been appointed Athersys Board Chair. Read more here: https://buff.ly/3F2IxB0
09/28/2023
We hosted our 2023 Annual Meeting of Stockholders yesterday. In case you missed it, you can listen to a replay here -
ATHERSYS, INC.'s Virtual Shareholder's Meeting - Thank you page ATHERSYS, INC.'s meeting has concluded. A replay will be available in 24 hours at: www.virtualshareholdermeeting.com/ATHX2023
09/27/2023
Our Annual Meeting will begin at 8:30 a.m. ET this morning. Stockholders and guests can join beginning now here:
ATHERSYS, INC.'s Virtual Shareholder's Meeting - Login page Please complete the required fields below to access the meeting as a stockholder. For assistance, please call Phone number844-986-0822 (US) or Phone number303-562-9302 (International).
09/26/2023
Tomorrow is our Annual Meeting of Stockholders. The meeting will begin at 8:30 a.m. ET. If you're a stockholder, please have your control number ready. Both stockholders and guests can join 15 minutes prior to the start of the meeting.
ATHERSYS, INC.'s Virtual Shareholder's Meeting - Pre meeting message page ATHERSYS, INC. is hosting a Virtual Stockholder Meeting on Wednesday, September 27, 2023 at 08:30 AM, Eastern Time, and the stockholders of record will be able to vote and ask questions online during the meeting. If you would like to attend the virtual meeting and have your control number, please lo...
Click here to claim your Sponsored Listing.
Contact the practice
Website
Address
3201 Carnegie Avenue
Cleveland, OH
44115
Alerts
Be the first to know and let us send you an email when Athersys posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.